Please login to the form below

Not currently logged in
Email:
Password:

Xalkori

This page shows the latest Xalkori news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s Talzenna cleared for breast cancer in Europe

Pfizer’s Talzenna cleared for breast cancer in Europe

Talzenna is one of four new targeted therapies it is hoping will drive growth in cancer, along with Xalkori follow-up Lorbrena (lorlatinib) in second-line ALK-positive NSCLC, SMO inhibitor ... The latest approval is another pillar in its bid to rebuild

Latest news

More from news
Approximately 21 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    In addition Merck KGaA also gets the right to co-promote Xalkori in the US and other "key" markets.

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    of Xalkori, below - the drug can achieve accelerated approval on the basis of an interim analysis or phase II data before OS is established. ... Outcome. Xalkori(crizotinib) in NSCLC. No OS benefit shown but positive data in morbidity (symptom improvement

  • Who tops the pharma list? Who tops the pharma list?

    Pfizer's Xalkori is just one example of this.”. Alongside oncology, treatments for immunology and metabolic diseases rank among the fastest-growing therapeutic classifications.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics